INVASIVE INTERVENTIONS IN STRUCTURAL HEART DISEASES: COMPREHENSIVE TECHNIQUES

Invasive Interventions in Structural Heart Diseases-kapak

TRICUSPID VALVE INTERVENTIONAL PROCEDURES: LONG-TERM OUTCOMES AND FOLLOW-UPS 359

Mehmet Karaca

Üsküdar University, Faculty of Medicine, Ataşehir Memorial Hopital, Department of Cardiology, İstanbul, Türkiye

Karaca M. Tricuspid Valve Interventional Procedures: LongTerm Outcomes and Follow-Up. In: Tanık VO, Özlek B, editors. Invasive Interventions in Structural Heart Diseases: Comprehensive Techniques. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.359-365.

ABSTRACT

Tricuspid valve pathologies, particularly tricuspid regurgitation (TR), are increasingly recognized as independent contributors to mortality. While surgical treatment remains a secondary option, interventional procedures have emerged as promising alternatives. The Cardioband device demonstrated significant improvements in NYHA class and echocardiographic parameters, with sustained benefits over 2 years. The Pascal system showed a 90% procedural success rate and improved clinical outcomes at 1 year. The Triclip device, assessed in the TRILUMINATE study, resulted in sustained clinical and echocardiographic improvements over 3 years, with minimal device-related complications. The Evoque system showed promising safety and efficacy in high-risk patients, with significant functional and echocardiographic improvements at 1 year. Interventional procedures for TR are safe and effective, offering substantial clinical and echocardiographic benefits. However, most devices lack randomized controlled trial data, limiting definitive conclusions. The ongoing randomized evaluation of the Triclip device may provide robust evidence to guide future clinical practice. Further research is essential to establish the long-term efficacy and safety of these innovative treatments.

Keywords: Tricuspid regurgitation; Interventional cardiology; Cardioband; Triclip; Pascal system; Evoque; Long-term outcomes; Clinical trials

Referanslar

  1. Braunwald NS, Ross J Jr, Morrow AG. Conservative management of tricuspid regurgitation in patients undergoing mitral valve replacement. Circulation. 1967;35(4 Suppl):I63-I69. [Crossref]
  2. Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, Tribouilloy C, Benfari G, Michelena H. Tricuspid regurgitation is a public health crisis. Prog Cardiovasc Dis. 2019;62(6):447-451. [Crossref]  [PubMed]
  3. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, et al. Tricuspid regurgitation and longterm clinical outcomes. Eur Heart J Cardiovasc Imaging. 2020;21(2):157-165. [Crossref]  [PubMed]
  4. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease [published correction appears in Eur Heart J. 2022;43(21):2022. Eur Heart J. 2022;43(7):561-632. [Crossref]  [PubMed]
  5. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force onPractice Guidelines [published correction appears in J Am Coll Cardiol. 2014 Jun 10;63(22):2489]. J Am Coll Cardiol. 2014;63(22):2438-2488. [Crossref]  [PubMed]
  6. Nickenig G, Weber M, Schueler R, Hausleiter J, Näbauer M, von Bardeleben RS, et al. 6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With Severe Tricuspid Regurgitation. J Am Coll Cardiol. 2019;73(15):1905-1915. [Crossref]  [PubMed]
  7. Nickenig G, Weber M, Schüler R, Hausleiter J, Nabauer M, von Bardeleben RS, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16(15):e1264-e1271. Published 2021 Feb 5. [Crossref]  [PubMed]  [PMC]
  8. Gray WA, Abramson SV, Lim S, Fowler D, Smith RL, Grayburn PA, et al. 1-Year Outcomes of Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study. JACC Cardiovasc Interv. 2022;15(19):1921-1932. [Crossref]  [PubMed]
  9. Kodali SK, Hahn RT, Davidson CJ, Narang A, Greenbaum A, Gleason P, et al. 1-Year Outcomes of Transcatheter Tricuspid Valve Repair. J Am Coll Cardiol. 2023;81(18):1766-1776. [Crossref]  [PubMed]
  10. Nickenig G, Weber M, Lurz P, von Bardeleben RS, Sitges M, Sorajja P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study [published correction appears in Lancet. 2020;395(10227):870. Lancet. 2019;394(10213):2002-2011. [Crossref]  [PubMed]
  11. Lurz P, Stephan von Bardeleben R, Weber M, Sitges M, Sorajja P, Hausleiter J, et al. Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation. J Am Coll Cardiol. 2021;77(3):229-239. [Crossref]  [PubMed]
  12. von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M, et al. Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial. Circ Cardiovasc Interv. 2023;16(8):e012888. [Crossref]  [PubMed]
  13. Nickenig G, Lurz P, Sorajja P, von Bardeleben RS, Sitges M, Tang GHL, et al. Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation: 3-Year Outcomes From the TRILUMINATE Study. JACC Cardiovasc Interv. 2024;17(18):2113- 2122. [Crossref]  [PubMed]
  14. Tang GHL, Hahn RT, Whisenant BK, Hamid N, Naik H, Makkar RR, et al. Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort. J Am Coll Cardiol. Published online October 28, 2024. [Crossref]  [PubMed]
  15. Fam NP, von Bardeleben RS, Hensey M, Kodali SK, Smith RL, Hausleiter J, et al. Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System: A Multicenter, Observational, First-in-Human Experience. JACC Cardiovasc Interv. 2021;14(5):501-511. [Crossref]  [PubMed]
  16. Webb JG, Chuang AM, Meier D, von Bardeleben RS, Kodali SK, Smith RL, et al. Transcatheter Tricuspid Valve Replacement With the EVOQUE System: 1-Year Outcomes of a Multicenter, First-in-Human Experience. JACC Cardiovasc Interv. 2022;15(5):481-491. [Crossref]  [PubMed]
  17. Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, et al. Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J. 2023;44(46):4862-4873. [Crossref]  [PubMed]